/
CorMedix Inc. (collectively, with our wholly owned subsidiaries, referred to herein as we, us, our or the Company ) is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Our primary focus has been commercializing DefenCath (taurolidine and heparin), in the U.S., which we launched in 2024 in the hemodialysis se…
Margins and capital returns are both well above average: 48.17% operating margin, ROIC at 47.93%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 617.0% YoY with margins expanding 99.6pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$400M
▲ +617.0% YoY
Net Income (TTM)
$181M
▲ +1009.4% YoY
Op. Margin
48.41%
▲ +99.6pp YoY
ROIC
47.69%
▲ +70.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$195M
▲ +440.6% YoY
Op. Cash Flow (TTM)
$198M
▲ +445.8% YoY
Net Debt
-$178M
Net Cash Position
Cash & Equiv.
$178M
5Y CAGR: +305.8%
Continue Research